These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33493500)

  • 1. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
    Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
    Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
    Mendez LC; Ravi A; Chung H; Tseng CL; Wronski M; Paudel M; McGuffin M; Cheung P; Loblaw A; Morton G
    Brachytherapy; 2018; 17(2):291-297. PubMed ID: 29137956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer.
    Tsang YM; Vignarajah D; Mcwilliam A; Tharmalingam H; Lowe G; Choudhury A; Hoskin P
    Br J Radiol; 2020 Feb; 93(1106):20190760. PubMed ID: 31778319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.
    Gomez-Iturriaga A; Buchser D; Mayrata E; San Miguel I; Gonzalez A; Suarez F; Martinez-Indart L; Minguez P; Espinosa J; Perez F; Cacicedo J; Casquero F
    Radiother Oncol; 2020 May; 146():16-20. PubMed ID: 32086047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
    Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
    Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial.
    Armstrong S; Brown S; Stancliffe M; Ostler P; Hughes R; Hoskin P; Alonzi R
    Radiother Oncol; 2021 Jun; 159():67-74. PubMed ID: 33766703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
    Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
    Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
    Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
    Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
    Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study.
    Tharmalingam H; Tsang Y; Ostler P; Wylie J; Bahl A; Lydon A; Ahmed I; Elwell C; Nikapota AR; Hoskin PJ;
    Radiother Oncol; 2020 Feb; 143():95-100. PubMed ID: 32044166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
    Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
    Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
    le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.
    Alayed Y; Loblaw A; McGuffin M; Chung HT; Tseng CL; D'Alimonte L; Cheung P; Liu S; Chu W; Szumacher E; Helou J; Ravi A; Haider M; Mamedov A; Zhang L; Morton G
    Radiother Oncol; 2021 Jan; 154():29-35. PubMed ID: 32918971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
    Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
    Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.